In 45, <= 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab (R)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11 q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile / Mauro, Francesca Romana; Molica, S; Laurenti, L; Cortelezzi, A; Carella, Am; Zaja, F; Chiarenza, A; Angrilli, F; Nobile, F; Marasca, R; Musolino, C; Brugiatelli, M; Piciocchi, A; Vignetti, Marco; Fazi, P; Gentile, Giuseppe; De Propris, Ms; DELLA STARZA, Irene; Marinelli, Marilisa; Chiaretti, Sabina; DEL GIUDICE, Ilaria; Nanni, M; Albano, F; Cuneo, A; Guarini, Anna; Foa, Roberto. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 38:2(2014), pp. 198-203. [10.1016/j.leukres.2013.11.009]
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
MAURO, Francesca Romana;VIGNETTI, Marco;GENTILE, Giuseppe;DELLA STARZA, IRENE;MARINELLI, MARILISA;CHIARETTI, sabina;DEL GIUDICE, ILARIA;GUARINI, Anna;FOA, Roberto
2014
Abstract
In 45, <= 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab (R)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11 q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic featuresI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
